Schedule

Take a look at what’s in store for the 2021 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance. 

Wednesday, Dec. 8

The New Winds Pushing and Pulling Antibacterial Development

9 - 9:05 a.m. EDT
Opening and Welcome
  • Christine Årdal, MBA, Ph.D.
 
9:05 - 9:25 a.m. EDT
Global Strategy on R&D Preparedness Against AMR

Keynote Speaker
  • Louise Norton-Smith, M.A., Head of Global AMR Strategy, U.K. Department of Health and Social Care 


9:25 -10:25 a.m. EDT
Panel 1: How Are We Going to Move to Paying for Population Health Benefits for Antibiotics?

9:25- 9:30 a.m. EDT
  • Moderator: David Shlaes, Ph.D., M.D.

9:30 - 9:45 a.m. EDT
Part A: Why the Market Isn’t Paying for Population-Level Health Benefits from Antibiotics?
  • Kevin Outterson, J.D., Boston University, School of Law, Boston, Mass. (Presentation time: 5 mins)
  • Beth Woods, MSc., Centre for Health Economics, University of York, U.K. (Presentation time: 10 mins)

9:45 - 10:05 a.m. EDT
Part B: Coming Soon: Pull Incentives with Clear Targets
 
Points System
  • Colm Leonard, M.D., National Institute for Health and Care Excellence (Presentation time: 5 mins)
  • Nick Crabb Ph.D., National Institute for Health and Care Excellence
 
PASTEUR Process Starting at IND 
  • Emily Wheeler, Biotechnology Innovation Organization (Presentation time: 5 mins)
 
PASTEUR “Favorable Characteristics” 
  • Helen Boucher, M.D., FACP, FIDSA , Interim Dean Tufts School of Medicine, IDSA Officer (Presentation time: 5 mins)

Overview of Other EU Pull Incentives in Play Today 
  • Christine Årdal, MBA, Ph.D., Norwegian Institute of Public Health (Presentation time: 5 mins)


10:05 -10:25 a.m. EDT
Panel 1: Part B Discussion


10:25 - 10:30 a.m. EDT
Break
 

10:30 - 11:30 a.m. EDT
Panel 2: Implications of This New Commercial Reality: Hit These Targets! 
  • Moderator: Kevin Outterson, J.D. 
  • Q&A Facilitator: Christine Årdal, MBA, Ph.D.
 
10:30 - 11:15 a.m. EDT
Seeking Diversity in Preclinical Science – Implications for CARB-X Strategy 
  • Erin Duffy, Ph.D., Chief of Research and Development, CARB-X (Presentation time: 5 mins)
 
Clinical Trials – Limits on the Kind of Data that Can be Generated and Why Superiority is So Hard 
  • John Rex, M.D., AMR Solutions (Presentation time: 10 mins)

The Perspective of the AMR Action Fund: If You Want Us to Partner with you, Either: (1) Demonstrate (Unexploited Niches) Commercial Potential, or (2) Hit the Targets from the U.K. Pilot and Future Pull Incentives Like PASTEUR & The Emerging EU Strategy AMR Action Fund - Set the Bar high, But Not Too High
  • Henry Skinner, Ph.D., CEO, AMR Action Fund (Presentation time: 5 mins)
 
Perspective from a Small US Company 
  • Mike Dudley, Pharm.D., FIDSA, CEO, Qpex (Presentation time: 5 mins)
 
Perspective of small European companies -BEAM Alliance 
  • Marc Gitzinger, Ph.D.,Vice President BEAM Alliance, CEO BioVersys (Presentation time: 5 mins)
 
Perspective of Large Companies – At What Stage Would a Big Pharma Buy a Compound? 
  • James Anderson, MBA, Executive Director, Global Health, IFPMA (Presentation time: 5 mins)

Perspective of a Country from LMIC 
  • Anand Anandkumar, M.S., Ph.D., CEO Bugworks (Presentation time: 5 mins)
 
Global Health Priorities 
  • Valeria Gigante, Ph.D., R&D Coordination Team Lead, WHO (Presentation time: 5 mins)

11:15 - 11:30 a.m. EDT
Panel 2 Discussion
 

11:30 - 11:40 a.m.  EDT
Closing Remarks
Summary of Lessons Learned from Today’s Program 
  • Christine Årdal, MBA, Ph.D.
  • Kevin Outterson, J.D.

Thursday, Dec. 9

AMR Boot Camp- What Makes a Good Project Succeed?

(Supported by CARB-X, GARDP, REPAIR Impact Fund and JPIAMR)

9-11 a.m. EDT

Moderators

  • Ursula Theuretzbacher, Ph.D., Center for Anti-Infective Agents
  • Sumathi Nambiar, M.D., MPH, Johnson & Johnson


What is Needed to Build an Attractive Discovery and Preclinical Project? 

9-9:05 a.m EDT

  • Introductions

9:05-9:35 a.m. EDT

  • Lloyd Czaplewski¸ B.Sc., Ph.D., Chemical Biology Ventures Ltd (Presentation time: 30 mins)

What Clinical Development Program is Needed to Show a Benefit for Patients and Society

9:35 - 10:05 a.m. EDT
  • Speaker TBD (Presentation time: 30 mins)

10:05-10:35 a.m. EDT
  • Subasree Srinivasan, M.D., MPH, Global Antibiotic R&D Partnership (GARDP)  (Presentation time: 30 mins)

10:35-11 a.m. EDT
  • Q& A and Open Discussion

Program Committee

Co-Chair
Sujata M. Bhavnani, Pharm.D., M.S., FIDSA       
Institute for Clinical Pharmacodynamics, Inc.       
Schenectady, N.Y.

Co-Chair
Shampa Das, BSc., Ph.D.                   
University of Liverpool   
Liverpool, United Kingdom
              
David R. Andes, M.D.
University of Wisconsin            
Madison, Wis.

Mariana Castanheira, Ph.D.
JMI Laboratories
North Liberty, Iowa

Marco Cavaleri, Ph.D.                            
European Medicines Agency       
London, United Kingdom

Mike Dawson, B.A., Ph.D.
Mike Dawson Antimicrobial Research Consultancy Ltd
Hitchin, United Kingdom

Martin Everett, BSc., Ph.D.
Antabio
Labège, France

Jeff Loutit​, M.D.
Qpex Biopharma
San Diego, Calif.

Sumathi Nambiar, M.D., MPH      
Johnson & Johnson         
Silver Spring, Md.       

Susanne Paukner, Ph.D.
Nabriva Therapeutics GmbH
Dublin, Ireland
   
William Hope, BMBS, FRACP, FRCPA, Ph.D.
University of Liverpool
Liverpool, United Kingdom

John H. Rex, M.D.                
F2G, Limited.     
Eccles, United Kingdom

Keith A. Rodvold, Pharm.D., FCCP, FIDSA             
University of Illinois at Chicago   
Chicago, Ill.          

Ursula Theuretzbacher, Ph.D.                                
Center for Anti-Infective Agents 
Vienna, Austria